Published by Wu YaNan | May 20, 2026

With growing national attention to the biomedical sector, the biopharmaceutical equipment market embraces broad development prospects.

In 2026, standing at the historical juncture of the launch of the 15th Five-Year Plan and the in-depth advancement of the bioeconomy, China's biopharmaceutical equipment industry is shifting from the initial stage of scale expansion to a new phase of value exploration. According to the 2025-2030 Full-scale Market Research and Investment Strategy Report on China's Biopharmaceutical Equipment Industry compiled by China Research and Intelligence, the industry has completely stepped out of the extensive development mode featuring heavy reliance on imports and low-end imitation. It has entered a new high-quality development cycle driven by intelligent transformation, domestic breakthroughs and industrial ecosystem competition. The market still has immense untapped potential, and a new era for the industry has just begun.

Five years ago, the biopharmaceutical equipment market was largely dominated by multinational giants, with domestic manufacturers playing a supplementary role. Today, the industrial landscape has evolved into a brand-new ecosystem shaped by policy guidance, technological breakthroughs and market demand. China Research and Intelligence describes this transformation as a historic leap from technological dependence to independent controllability, which is an accurate reflection of the real industry landscape.

The competitive pattern has shifted from foreign monopoly to the rise of domestic brands. In the past, foreign enterprises including Sartorius, Thermo Fisher and Pall held an overwhelming share in the high-end biopharmaceutical equipment market thanks to profound technological accumulation and comprehensive product lines, leaving limited room for domestic players. At present, the situation has been thoroughly changed. Leading domestic companies such as Tofflon, CTT and Nano-Micro Technology have achieved rapid growth in the mid-to-low-end market and gradually penetrated the high-end segment, leveraging advantages in localized supply chains, continuous technological innovation and flexible services.

Technology has evolved from auxiliary tools to core infrastructure. In 2026, biopharmaceutical equipment has broken the boundaries of traditional mechanical devices and achieved substantial upgrading with intelligent and digital technologies. In the field of intelligent control, multi-modal sensor fusion enables simultaneous monitoring of temperature, pressure, metabolites and other parameters. The collaborative framework of edge computing and cloud computing minimizes data processing latency. Adaptive control algorithms based on reinforcement learning equip the equipment with a closed-loop capability of perception, decision-making and execution.

Policies have been upgraded from encouraging trials to systematic technological breakthroughs. The 2026 Government Work Report officially listed biomedicine as a new pillar industry, which fully demonstrates strong national support. Special re-loans launched by the National Development and Reform Commission give priority to high-end biopharmaceutical equipment. The 14th Five-Year Plan for Bioeconomy Development issued by the Ministry of Industry and Information Technology takes bio-manufacturing as a key project to accelerate the independent development of relevant equipment.

Meanwhile, reforms on drug review and approval have been further deepened, greatly shortening the launch cycle of innovative medicines. It allows patients to access cutting-edge therapies at an earlier time, and also pushes equipment manufacturers to accelerate technological iteration. As pointed out in the research report, the combined policies have paved the way for laboratory technologies to be applied in large-scale production. The biopharmaceutical equipment industry is poised to reap intensive policy dividends during the 15th Five-Year Plan period.

To assess the market of biopharmaceutical equipment, it is essential to analyze growth drivers and structural changes rather than merely focusing on figures. Research shows that China's biopharmaceutical equipment industry is in a period of rapid expansion with sound growth quality.

The overall market has reached a considerable scale, with growth rate leading major markets worldwide. The domestic market has expanded multiple times in recent years, maintaining a high compound annual growth rate well above the global average. It is projected to hit a new milestone around 2030. Notably, the growth is driven by genuine market demand instead of low-price subsidies.

Growth momentum varies across segmented sectors. Cell culture and fermentation equipment ranks first by market share, enjoying robust growth supported by expanding biopharmaceutical production capacity and the popularization of single-use technologies. Separation and purification equipment takes the second place, with AI-powered intelligent chromatography systems and high-precision membrane separation technologies fueling market expansion. Modular and flexible production lines have become mainstream for pharmaceutical preparation and packaging equipment, greatly improving capacity utilization and response efficiency. As an emerging track, continuous manufacturing equipment registers a growth rate far higher than the industry average with rapidly rising market penetration. Continuous manufacturing and intelligent integrated systems will serve as the core growth engines in the years ahead.

The industry presents a clustered regional development pattern. Three major industrial clusters have taken shape in the Yangtze River Delta, Pearl River Delta and Bohai Rim regions. Innovation hubs including Zhangjiang in Shanghai, Suzhou BioBAY and Yizhuang in Beijing gather leading enterprises and research institutions, delivering improved industrial chain collaboration. Central and western China focus on featured segments and achieve differentiated development with policy and resource support. In addition, the export volume of domestic biopharmaceutical equipment keeps rising, with growing global market share. Emerging markets in Southeast Asia and the Middle East witness particularly fast growth.

Value stratification is reshaping the profit structure of the industry. High-end equipment customized for innovative pharmaceutical enterprises and large CDMOs enjoys strong brand premium. Standardized mass-produced products meet basic market demands, and leading enterprises cut costs via full industrial chain integration to gain competitive edges and risk resistance. Specialized equipment for cutting-edge fields such as cell therapy and gene therapy, as well as products for synthetic biology and other cross-border areas, tap into emerging markets. This three-track development pattern, featuring high-end leadership, mass market support and emerging sector breakthroughs, keeps unlocking new growth potential for the industry.

The industrial chain of biopharmaceutical equipment consists of three major links: upstream core components, midstream complete equipment manufacturing and system integration, and downstream application scenarios, forming a complete value chain from core technologies to end-use services.

Upstream: Localization of core components revitalizes the whole industry. The upstream sector covers stainless steel materials, sensors, membrane filtration components, chromatographic fillers and other key parts, which are the foundation of the industry. For a long time, high-end sensors, precision pumps and valves, and high-performance membrane materials relied heavily on imports, restricting the quality improvement of domestic equipment. Substantial progress has been made in this regard in 2026. Domestic enterprises have achieved independent R&D and made breakthroughs in multiple core technologies previously controlled by foreign suppliers. The localization of upstream components reduces reliance on overseas technologies, and promotes the popularization of biopharmaceutical equipment by cutting overall costs and improving cost performance.

Midstream: Transformation from equipment sales to solution services accelerates. Midstream manufacturers improve operational efficiency through intelligent and standardized management. Leading companies build smart production bases equipped with AI visual inspection and automatic packaging systems, achieving remarkable progress in product consistency and production efficiency. Modular design has become mainstream. Standardized interfaces enable rapid combination of different functional modules, allowing a single production line to manufacture diverse products.

Downstream: Booming application scenarios fuel sustained growth. Industrial applications extend from traditional pharmaceutical production to high-end fields such as biopharmaceuticals, cell therapy and gene therapy. Close cooperation between CDMOs and pharmaceutical companies drives strong demand for high-performance equipment. Meanwhile, demand for high-throughput screening devices and compact intelligent platforms surges in R&D scenarios. Biopharmaceutical equipment has evolved from simple production tools into core infrastructure supporting the entire biomedical innovation chain. Its technological independence, stable supply and cost controllability have become key indicators of China's fundamental productivity in the biomedical sector.

The rise of the biopharmaceutical equipment industry results from the pursuit of technological self-reliance and the prosperity of the bioeconomy. It embodies China's progress in biomedicine from following others to keeping pace with global leaders, and even taking the lead in certain fields.

The future of the biopharmaceutical equipment industry lies in empowering the biomedical sector rather than replacing existing players. As a key driver for popularizing accessible medicines, improving production accuracy and building a green industrial ecosystem, it will continue to facilitate the upgrading of the entire biomedical industry.